Shanghai RAAS Blood Products Co Ltd Class A - Asset Resilience Ratio
Shanghai RAAS Blood Products Co Ltd Class A (002252) has an Asset Resilience Ratio of 2.03% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Shanghai RAAS Blood Products Co Ltd Clas's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Shanghai RAAS Blood Products Co Ltd Class A's Asset Resilience Ratio has changed over time. See how leveraged is Shanghai RAAS Blood Products Co Ltd Clas's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shanghai RAAS Blood Products Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Shanghai RAAS Blood Products Co Ltd Clas.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥765.31 Million | 2.03% |
| Total Liquid Assets | CN¥765.31 Million | 2.03% |
Asset Resilience Insights
- Limited Liquidity: Shanghai RAAS Blood Products Co Ltd Class A maintains only 2.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai RAAS Blood Products Co Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Shanghai RAAS Blood Products Co Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 11.64% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653 |
Biotechnology | 56.48% |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670 |
Biotechnology | 9.82% |
Annual Asset Resilience Ratio for Shanghai RAAS Blood Products Co Ltd Class A (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Shanghai RAAS Blood Products Co Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.02% | CN¥765.31 Million ≈ $111.99 Million |
CN¥37.80 Billion ≈ $5.53 Billion |
-2.86pp |
| 2024-12-31 | 4.89% | CN¥1.64 Billion ≈ $240.54 Million |
CN¥33.63 Billion ≈ $4.92 Billion |
+4.27pp |
| 2023-12-31 | 0.62% | CN¥197.41 Million ≈ $28.89 Million |
CN¥31.93 Billion ≈ $4.67 Billion |
-0.16pp |
| 2022-12-31 | 0.78% | CN¥237.77 Million ≈ $34.79 Million |
CN¥30.46 Billion ≈ $4.46 Billion |
-0.02pp |
| 2021-12-31 | 0.81% | CN¥219.38 Million ≈ $32.10 Million |
CN¥27.24 Billion ≈ $3.99 Billion |
-0.22pp |
| 2020-12-31 | 1.03% | CN¥262.14 Million ≈ $38.36 Million |
CN¥25.49 Billion ≈ $3.73 Billion |
-1.46pp |
| 2019-12-31 | 2.49% | CN¥295.40 Million ≈ $43.23 Million |
CN¥11.85 Billion ≈ $1.73 Billion |
-0.38pp |
| 2018-12-31 | 2.87% | CN¥327.05 Million ≈ $47.86 Million |
CN¥11.40 Billion ≈ $1.67 Billion |
-18.83pp |
| 2017-12-31 | 21.70% | CN¥3.14 Billion ≈ $458.95 Million |
CN¥14.46 Billion ≈ $2.12 Billion |
+5.39pp |
| 2016-12-31 | 16.31% | CN¥2.16 Billion ≈ $315.65 Million |
CN¥13.23 Billion ≈ $1.94 Billion |
+2.35pp |
| 2015-12-31 | 13.96% | CN¥1.61 Billion ≈ $236.05 Million |
CN¥11.56 Billion ≈ $1.69 Billion |
+13.94pp |
| 2014-12-31 | 0.02% | CN¥2.00 Million ≈ $292.66K |
CN¥9.38 Billion ≈ $1.37 Billion |
-6.32pp |
| 2013-12-31 | 6.35% | CN¥99.96 Million ≈ $14.63 Million |
CN¥1.58 Billion ≈ $230.49 Million |
-- |
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinoge… Read more